Instil
instil.io
Actively hiring
Professional Services
Nonprofits & Foundations
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
Greycroft, USVP
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2020
Founded
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Greycroft 
USVP Similar startupsby what they do, their industry and backers
Boardable is the board management software designed specifically for nonprofits. We do more nonprofits, so they can do more for others.
Givebutter is a leading platform for fundraising for nonprofits, offering an intuitive UI and low fees.
With Chariot, nonprofits can raise more from Donor-Advised Funds and save time on gift processing.
Our Happiness Platform combines authentic communication tools, dedicated success specialists and AI to help you build lasting relationships.
Civitech is a company that modernizes advocacy and campaign work by providing best-in-class civic tools that are both affordable and…
On Change.org, more than half a billion people across 196 countries are starting campaigns, mobilizing supporters, and working with…
News
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
DALLAS, May 15, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (
Read more
Report
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
GlobeNewswire Press Release.
Read more
Report
Signs and portents for 2021
Garth's annual review of trends emerging from this year, and predictions for the next.
Read more
Report
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
US phase 1 trial of '2510 is expected to be initiated before the end of 2025 Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of '2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE
Read more
Report
Report
Pro access
Upgrade to see all 16 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.